Literature DB >> 16508882

Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia.

Sungmin Kiem1, Jerome J Schentag.   

Abstract

Although minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) have been used as the most popular prediction tools for antimicrobial action, they have shortcomings. The MIC and MBC do not consider time-related antimicrobial effects, such as killing rate and postantibiotic effect. In this regard, the concept of pharmacokinetic and pharmacodynamic (PK/PD) modeling has been introduced to help interpret determinations of susceptibility breakpoints. Although area under the inhibitory concentration-time curve (AUIC) can be used as a universal PK/PD parameter, target magnitudes of the parameter have to be high enough to exert rapid bactericidal activity (> 250) and to prevent selection and induction of resistance (> 100). For vancomycin used in treatment of methicillin-resistant Staphylococcus aureus pneumonia, a much higher AUIC (400) is suggested to avoid treatment failure. For resistant gram-negative bacteria, such as Pseudomonas aeruginosa, the usual dosage of fourth-generation cephalosporins, carbapenems, and fluoroquinolones cannot achieve the target AUICs. Either combination therapy or higher dosage should be administered to achieve target AUICs and prevent the potential for failure. Unresolved issues, such as influence of protein binding, PK/PD at tissue sites versus blood, the impact of the immune system, should be addressed to refine the applicability of PK/PD in antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16508882     DOI: 10.1055/s-2006-933674

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  6 in total

1.  Susceptible, intermediate, and resistant - the intensity of antibiotic action.

Authors:  Arne Rodloff; Torsten Bauer; Santiago Ewig; Peter Kujath; Eckhard Müller
Journal:  Dtsch Arztebl Int       Date:  2008-09-26       Impact factor: 5.594

Review 2.  Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

Authors:  Justin L Wong; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-03-01       Impact factor: 2.878

3.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

4.  Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance.

Authors:  D E Ghannam; G H Rodriguez; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-28       Impact factor: 3.267

5.  Activities of tobramycin and polymyxin E against Pseudomonas aeruginosa biofilm-coated medical grade endotracheal tubes.

Authors:  Keiko Tarquinio; Kelsey Confreda; James Shurko; Kerry LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191

6.  In Vitro Comparison of Antibacterial and Antibiofilm Activities of Selected Fluoroquinolones against Pseudomonas aeruginosa and Methicillin-Resistant Staphylococcus aureus.

Authors:  Majed M Masadeh; Karem H Alzoubi; Wesam S Ahmed; Aisha S Magaji
Journal:  Pathogens       Date:  2019-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.